Verification evidence is still being completed.
PDF / print export
Asgard Therapeutics
Lund, Sweden
- Verified lead
- Cristiana Pires
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Co-Founder and CEO
- 2026 technical specialization
- Cancer Immunotherapy, Direct Cell Reprogramming, Oncology, and Platform Therapeutics Development
- Review cycle
- May 2026
- Full address
- Asgard Therapeutics AB, Medicon Village, Scheelevagen 2, 223 81 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Asgard Therapeutics contact page confirming the Lund address.
- Editorial note
- Asgard Therapeutics is published because official company materials confirm current leadership, Lund operating address, and a real immunotherapy platform with Swedish operating depth.
Cancer Immunotherapy, Direct Cell Reprogramming, Oncology, and Platform Therapeutics Development
Official leadership disclosure, Official Lund address disclosure, Therapeutics platform claim
Asgard Therapeutics is published because official company materials confirm current leadership, Lund operating address, and a real immunotherapy platform with Swedish operating depth.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
Asgard Therapeutics
Cancer Immunotherapy, Direct Cell Reprogramming, Oncology, and Platform Therapeutics Development · Early-stage therapeutics platform
Asgard Therapeutics runs cancer immunotherapy development, cell reprogramming platform work, and early-stage therapeutics programs in Lund, Sweden.
- Lead
- Cristiana Pires (verified ↗)
- Address
- Asgard Therapeutics AB, Medicon Village, Scheelevagen 2, 223 81 Lund, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Early-stage therapeutics platform
- Capabilities
- Cancer Immunotherapy Development · Cell Reprogramming Platform Work · Early-Stage Therapeutics Programs
- Founded
- 2018
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Cristiana Pires
Co-Founder and CEO
Full addressAsgard Therapeutics AB, Medicon Village, Scheelevagen 2, 223 81 Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Asgard Therapeutics contact page listing the Lund Medicon Village address.
Open sourceEarly-stage therapeutics platform
Lund, Sweden. Cancer Immunotherapy, Direct Cell Reprogramming, Oncology, and Platform Therapeutics Development. Review completed on 21 Mar 2026.
Swedish corporate and therapeutics-development oversight
Official leadership disclosure, Official Lund address disclosure, Therapeutics platform claim
Cancer Immunotherapy, Direct Cell Reprogramming, Oncology, and Platform Therapeutics Development
Asgard Therapeutics is published because official company materials confirm current leadership, Lund operating address, and a real immunotherapy platform with Swedish operating depth.
Editorial note
Asgard Therapeutics is published because official company materials confirm current leadership, Lund operating address, and a real immunotherapy platform with Swedish operating depth.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Cancer Immunotherapy Development
Cell Reprogramming Platform Work
Early-Stage Therapeutics Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Cell-reprogramming workflow
Immunotherapy R&D systems
Therapeutics development infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Asgard Therapeutics located?
- Asgard Therapeutics operates from Asgard Therapeutics AB, Medicon Village, Scheelevagen 2, 223 81 Lund, Sweden, Lund, Sweden.
- Who runs Asgard Therapeutics?
- Asgard Therapeutics is led by Cristiana Pires, Co-Founder and CEO. Verified 21 Mar 2026.
- What does Asgard Therapeutics do?
- Asgard Therapeutics runs cancer immunotherapy development, cell reprogramming platform work, and early-stage therapeutics programs in Lund, Sweden. Core capabilities: Cancer Immunotherapy Development, Cell Reprogramming Platform Work, Early-Stage Therapeutics Programs.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.